The Zacks Analyst Blog Microsoft, Novartis, RTX and Air T
Microsoft leads Zacks??? top research picks today, alongside Novartis and RTX, highlighting cloud, pharma innovation and defense demand shaping 2025.
NVS - Novartis AG
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
Stock News
B. Riley Wealth Advisors Inc. Invests $1.12 Million in Novartis AG $NVS
B. Riley Wealth Advisors Inc. bought a new stake in Novartis AG (NYSE: NVS) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought...
First Look: iRobot Bankruptcy, Netflix-WBD Fight, Tesla Robotaxi
Stock News iRobot enters Chapter 11: iRobot (IRBT) filed for Chapter 11 and agreed to be acquired by contract manufacturer Picea Robotics, saying operations and
Cullen Capital Management LLC Has $253.74 Million Stock Position in Novartis AG $NVS
Cullen Capital Management LLC lowered its stake in shares of Novartis AG (NYSE: NVS) by 0.6% during the second quarter, according to the company in its most recent Form 13F filing with the...
Geneos Wealth Management Inc. Increases Stock Holdings in Novartis AG $NVS
Geneos Wealth Management Inc. increased its stake in Novartis AG (NYSE: NVS) by 52.4% in the undefined quarter, according to the company in its most recent filing with the SEC. The institutional...
Balyasny Asset Management L.P. Increases Stock Holdings in Novartis AG $NVS
Balyasny Asset Management L.P. boosted its position in shares of Novartis AG (NYSE: NVS) by 52.9% during the second quarter, according to its most recent Form 13F filing with the Securities and...
Novartis breaks ground on flagship manufacturing hub in North Carolina
East Hanover, December 12, 2025 – Novartis, a leading global innovative medicines company, broke ground yesterday on its more than 700,000-square-foot flagship manufacturing hub in North Carolina,...
First Look: Fed Cut Looms; SpaceX IPO; J&J Myeloma Data; Google Probe
Stock News Fed set for a âhawkish cutâ: The Federal Reserve is widely expected to deliver a third 25 bp rate cut amid sharp divisions over inflation vs. job
Market Today: Fed Cut Looms, Nvidia's China Shift, Target's SoHo Push, OpenAI Taps Slack CEO
Stock News Fed set for âhawkish cut': Goldman Sachs (GS) and other Wall Street desks expect the Federal Reserve to deliver a third straight 25 bps rate cut wh
Novartis' Investigational Drug Reports Longer Disease Control In Patients With Rare Blood Disorder
Novartis AG (NYSE: NVS) on Tuesday shared results from the VAYHIT2 Phase 3 trial of ianalumab plus eltrombopag in patients with primary immune thrombocytopenia (ITP) previously treated with...
Novartis Drops $1.7 Billion on AI Allergy Breakthrough
Novartis (NVS) is doubling down on AI-driven drug discovery with a deal that could be worth $1.7 billion, signaling rising conviction that data-intensive platfo
Tiny Biotech Terns Takes Aim At Novartis' Leukemia Blockbuster
Terns Pharmaceuticals, Inc. (NASDAQ: TERN) on Monday presented updated and expanded data from the ongoing CARDINAL trial of TERN-701 in previously treated chronic myeloid leukemia (CML) patients...
First Look: Paramount's WBD bid, IBM-Confluent, Boeing-Spirit
Stock News Paramount goes hostile for WBD: Paramount Skydance (PSKY) launched a hostile, all-cash $30-per-share offer for Warner Bros. Discovery (WBD), valuing
Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses
Basel, December 9, 2025 – Novartis today announced positive results from VAYHIT2, a Phase III trial evaluating ianalumab plus eltrombopag in patients with primary immune thrombocytopenia (ITP)...
1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years
Basel, December 9, 2025 – Novartis today announced results showing that one in four patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced...
Relation announces strategic collaboration with Novartis to advance therapeutics for atopic diseases
LONDON, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Relation today announced a multi-program, strategic collaboration with Novartis to discover and advance novel targets for atopic diseases. Under the terms...
Market Today: IBM buys Confluent; Nvidia wins China chip nod
Stock News Paramount escalates WBD fight: Paramount Skydance (PSKY) launched a hostile all-cash $30 per share tender offer for Warner Bros. Discovery (WBD), val
Here's Why Novartis (NVS) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Novartis (NYSE:NVS) Shares Unloaded Rep. Lisa C. McClain
Representative Lisa C. McClain (R-Michigan) recently sold shares of Novartis AG (NYSE: NVS). In a filing disclosed on November 21st, the Representative disclosed that they had sold between $1,001...
Market Today: Stocks Rally, Tesla Robotaxi and Nvidia Scrutiny
Stock News Campbell's exec ousted after viral recording: Campbell Soup (CPB) said it terminated IT VP Martin Bally after an internal review concluded he was the
Price Targets
Novartis (NVS) PT Raised to $126 at CFRA
$126.00
(was $123.33)
Wan Nurhayati
·
CFRA
Novartis (NVS) PT Raised to $120 at BMO Capital
$120.00
(was $109.91)
Etzer Darout
·
BMO Capital
Novartis downgraded to Neutral from Buy at Goldman Sachs
$121.00
(was $119.38)
James Quigley
·
Goldman Sachs
Novartis (NVS) PT Raised to $118 at BMO Capital
$118.00
(was $106.13)
Etzer Darout
·
BMO Capital
Novartis (NVS) PT Raised to $108 at CFRA
$108.00
(was $97.27)
Wan Nurhayati
·
CFRA